{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:32:56Z","timestamp":1773189176647,"version":"3.50.1"},"reference-count":35,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T00:00:00Z","timestamp":1528848000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C552\/A17720"],"award-info":[{"award-number":["C552\/A17720"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000402","name":"Kay Kendall Leukaemia Fund","doi-asserted-by":"publisher","award":["KKL1050"],"award-info":[{"award-number":["KKL1050"]}],"id":[{"id":"10.13039\/501100000402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","award":["Synthetic Biology CTD"],"award-info":[{"award-number":["Synthetic Biology CTD"]}],"id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0350-x","type":"journal-article","created":{"date-parts":[[2018,6,14]],"date-time":"2018-06-14T01:23:53Z","timestamp":1528939433000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus\u00a0in murine cancer cells"],"prefix":"10.1136","volume":"6","author":[{"given":"Janet","family":"Lei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egon J.","family":"Jacobus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William K.","family":"Taverner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry D.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Hemmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katy","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorna","family":"Slater","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred","family":"Lilley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Champion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret R.","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3825-0841","authenticated-orcid":false,"given":"Len W.","family":"Seymour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,6,13]]},"reference":[{"key":"350_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","volume":"30","author":"SJ Russell","year":"2012","unstructured":"Russell SJ, Peng K-W, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30:658\u201370. https:\/\/doi.org\/10.1038\/nbt.2287 .","journal-title":"Nat Biotechnol"},{"key":"350_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/mt.2013.220","volume":"22","author":"ST Workenhe","year":"2014","unstructured":"Workenhe ST, Mossman KL. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther. 2014;22:251\u20136. https:\/\/doi.org\/10.1038\/mt.2013.220 .","journal-title":"Mol Ther"},{"key":"350_CR3","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s00109-016-1453-9","volume":"94","author":"BA Keller","year":"2016","unstructured":"Keller BA, Bell JC. Oncolytic viruses\u2014immunotherapeutics on the rise. J Mol Med. 2016;94:979\u201391. https:\/\/doi.org\/10.1007\/s00109-016-1453-9 .","journal-title":"J Mol Med"},{"key":"350_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.omto.2016.11.003","volume":"4","author":"A Dyer","year":"2017","unstructured":"Dyer A, Di Y, Calderon H, Illingworth S, Kueberuwa G, Tedcastle A, et al. Oncolytic group B adenovirus Enadenotucirev mediates non-apoptotic cell death with membrane disruption and release of inflammatory mediators. Mol Ther - Oncolytics. 2017;4:18\u201330. https:\/\/doi.org\/10.1016\/j.omto.2016.11.003 .","journal-title":"Mol Ther - Oncolytics."},{"key":"350_CR5","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3770","volume":"14","author":"BD Lichty","year":"2014","unstructured":"Lichty BD, Breitbach CJ, Stojdl DF, Bell JC. Going viral with cancer immunotherapy. Nat Rev Cancer. 2014;14:559\u201367. https:\/\/doi.org\/10.1038\/nrc3770 .","journal-title":"Nat Rev Cancer"},{"key":"350_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.virol.2012.10.034","volume":"435","author":"C Wu","year":"2013","unstructured":"Wu C, \u00d6berg D, Rashid A, Gupta R, Mignardi M, Johansson S, et al. A mouse mammary epithelial cell line permissive for highly efficient human adenovirus growth. Virology. 2013;435:363\u201371. https:\/\/doi.org\/10.1016\/j.virol.2012.10.034 .","journal-title":"Virology"},{"key":"350_CR7","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1525-0016(03)00199-0","volume":"8","author":"G Halld\u00e9n","year":"2003","unstructured":"Halld\u00e9n G, Hill R, Wang Y, Anand A, Liu T-C, Lemoine NR, et al. Novel immunocompetent murine tumor models for the assessment of replication-competent oncolytic adenovirus efficacy. Mol Ther. 2003;8:412\u201324. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12946314 . Accessed 8 Nov 2017","journal-title":"Mol Ther"},{"key":"350_CR8","doi-asserted-by":"crossref","first-page":"7674","DOI":"10.1128\/JVI.69.12.7674-7681.1995","volume":"69","author":"JD Guida","year":"1995","unstructured":"Guida JD, Fejer G, Pirofski LA, Brosnan CF, Horwitz MS. Mouse adenovirus type 1 causes a fatal hemorrhagic encephalomyelitis in adult C57BL\/6 but not BALB\/c mice. J Virol. 1995;69:7674\u201381. http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=189708&tool=pmcentrez&rendertype=abstract . Accessed 7 Feb 2016","journal-title":"J Virol"},{"key":"350_CR9","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1128\/JVI.74.6.2895-2899.2000","volume":"74","author":"I Ganly","year":"2000","unstructured":"Ganly I, Mautner V, Balmain A. Productive replication of human adenoviruses in mouse epidermal cells. J Virol. 2000;74:2895\u20139. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10684307 . Accessed 9 Feb 2018","journal-title":"J Virol"},{"key":"350_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/0042-6822(86)90406-X","volume":"148","author":"FA Eggerding","year":"1986","unstructured":"Eggerding FA, Pierce WC. Molecular biology of adenovirus type 2 semipermissive infections. I. Viral growth and expression of viral replicative functions during restricted adenovirus infection. Virology. 1986;148:97\u2013113. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/3942035 . Accessed 9 Feb 2018","journal-title":"Virology"},{"key":"350_CR11","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1128\/JVI.78.9.4454-4462.2004","volume":"78","author":"D Sirena","year":"2004","unstructured":"Sirena D, Lilienfeld B, Eisenhut M, K\u00e4lin S, Boucke K, Beerli RR, et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol. 2004;78:4454\u201362. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15078926 . Accessed 9 Feb 2018","journal-title":"J Virol"},{"key":"350_CR12","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1158\/0008-5472.CAN-05-3497","volume":"66","author":"MA Thomas","year":"2006","unstructured":"Thomas MA, Spencer JF, La Regina MC, Dhar D, Tollefson AE, Toth K, et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res. 2006;66:1270\u20136. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3497 .","journal-title":"Cancer Res"},{"key":"350_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.virol.2007.07.022","volume":"369","author":"JC Steel","year":"2007","unstructured":"Steel JC, Morrison BJ, Mannan P, Abu-Asab MS, Wildner O, Miles BK, et al. Immunocompetent syngeneic cotton rat tumor models for the assessment of replication-competent oncolytic adenovirus. Virology. 2007;369:131\u201342. https:\/\/doi.org\/10.1016\/j.virol.2007.07.022 .","journal-title":"Virology"},{"key":"350_CR14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1128\/JVI.72.1.415-419.1998","volume":"72","author":"JM Bergelson","year":"1998","unstructured":"Bergelson JM, Krithivas A, Celi L, Droguett G, Horwitz MS, Wickham T, et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol. 1998;72:415\u20139. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/9420240 . Accessed 10 Feb 2018","journal-title":"J Virol"},{"key":"350_CR15","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/nm952","volume":"9","author":"A Gaggar","year":"2003","unstructured":"Gaggar A, Shayakhmetov DM, Lieber A. CD46 is a cellular receptor for group B adenoviruses. Nat Med. 2003;9:1408\u201312. https:\/\/doi.org\/10.1038\/nm952 .","journal-title":"Nat Med"},{"key":"350_CR16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nm.2270","volume":"17","author":"H Wang","year":"2011","unstructured":"Wang H, Li Z-Y, Liu Y, Persson J, Beyer I, M\u00f6ller T, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med. 2011;17:96\u2013104. https:\/\/doi.org\/10.1038\/nm.2270 .","journal-title":"Nat Med"},{"key":"350_CR17","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1128\/JVI.06181-11","volume":"86","author":"HV Trinh","year":"2012","unstructured":"Trinh HV, Lesage G, Chennamparampil V, Vollenweider B, Burckhardt CJ, Schauer S, et al. Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection. J Virol. 2012;86:1623\u201337. https:\/\/doi.org\/10.1128\/JVI.06181-11 .","journal-title":"J Virol"},{"key":"350_CR18","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1038\/mt.2012.116","volume":"20","author":"A-M Young","year":"2012","unstructured":"Young A-M, Archibald KM, Tookman LA, Pool A, Dudek K, Jones C, et al. Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo. Mol Ther. 2012;20:1676\u201388. https:\/\/doi.org\/10.1038\/mt.2012.116 .","journal-title":"Mol Ther"},{"key":"350_CR19","doi-asserted-by":"publisher","first-page":"5676","DOI":"10.1128\/JVI.79.9.5676-5683.2005","volume":"79","author":"Q Xi","year":"2005","unstructured":"Xi Q, Cuesta R, Schneider RJ. Regulation of translation by ribosome shunting through phosphotyrosine-dependent coupling of adenovirus protein 100k to viral mRNAs. J Virol. 2005;79:5676\u201383. https:\/\/doi.org\/10.1128\/JVI.79.9.5676-5683.2005 .","journal-title":"J Virol"},{"key":"350_CR20","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1101\/gad.10.12.1557","volume":"10","author":"A Yueh","year":"1996","unstructured":"Yueh A, Schneider RJ. Selective translation initiation by ribosome jumping in adenovirus-infected and heat-shocked cells. Genes Dev. 1996;10:1557\u201367. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8666238 . Accessed 8 Feb 2016","journal-title":"Genes Dev"},{"key":"350_CR21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1101\/gad.14.4.414","volume":"14","author":"A Yueh","year":"2000","unstructured":"Yueh A, Schneider RJ. Translation by ribosome shunting on adenovirus and hsp70 mRNAs facilitated by complementarity to 18S rRNA. Genes Dev. 2000;14:414\u201321. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10691734 . Accessed 25 Apr 2018","journal-title":"Genes Dev"},{"key":"350_CR22","doi-asserted-by":"publisher","first-page":"e2409","DOI":"10.1371\/journal.pone.0002409","volume":"3","author":"I Kuhn","year":"2008","unstructured":"Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, et al. Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One. 2008;3:e2409. https:\/\/doi.org\/10.1371\/journal.pone.0002409 .","journal-title":"PLoS One"},{"key":"350_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.omto.2017.03.003","volume":"5","author":"S Illingworth","year":"2017","unstructured":"Illingworth S, Di Y, Bauzon M, Lei J, Duffy MR, Alvis S, et al. Preclinical safety studies of Enadenotucirev, a chimeric group B human-specific oncolytic adenovirus. Mol Ther - Oncolytics. 2017;5:62\u201374. https:\/\/doi.org\/10.1016\/j.omto.2017.03.003 .","journal-title":"Mol Ther - Oncolytics"},{"key":"350_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s40425-017-0277-7","volume":"5","author":"R Garcia-Carbonero","year":"2017","unstructured":"Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, et al. Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. J Immunother Cancer. 2017;5:71. https:\/\/doi.org\/10.1186\/s40425-017-0277-7 .","journal-title":"J Immunother Cancer"},{"key":"350_CR25","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.15252\/emmm.201707567","volume":"9","author":"JD Freedman","year":"2017","unstructured":"Freedman JD, Hagel J, Scott EM, Psallidas I, Gupta A, Spiers L, et al. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies. EMBO Mol Med. 2017;9:1067\u201387. https:\/\/doi.org\/10.15252\/emmm.201707567 .","journal-title":"EMBO Mol Med"},{"key":"350_CR26","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.virol.2017.02.011","volume":"505","author":"S-L Chia","year":"2017","unstructured":"Chia S-L, Lei J, Ferguson DJP, Dyer A, Fisher KD, Seymour LW. Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer. Virology. 2017;505:162\u201371. https:\/\/doi.org\/10.1016\/j.virol.2017.02.011 .","journal-title":"Virology"},{"key":"350_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/gt.2014.2","volume":"21","author":"Y Di","year":"2014","unstructured":"Di Y, Seymour L, Fisher K. Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood. Gene Ther. 2014;21:440\u20133. https:\/\/doi.org\/10.1038\/gt.2014.2 .","journal-title":"Gene Ther"},{"key":"350_CR28","doi-asserted-by":"publisher","first-page":"e0177810","DOI":"10.1371\/journal.pone.0177810","volume":"12","author":"N Marino","year":"2017","unstructured":"Marino N, Illingworth S, Kodialbail P, Patel A, Calderon H, Lear R, et al. Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes. PLoS One. 2017;12:e0177810. https:\/\/doi.org\/10.1371\/journal.pone.0177810 .","journal-title":"PLoS One"},{"key":"350_CR29","doi-asserted-by":"publisher","unstructured":"Tedcastle A, Illingworth S, Brown A, Seymour LW, Fisher KD. Actin resistant DNAse I expression from oncolytic adenovirus Enadenotucirev enhances its intratumoural spread and reduces tumour growth. Mol Ther. 2015; https:\/\/doi.org\/10.1038\/mt.2015.233 .","DOI":"10.1038\/mt.2015.233"},{"key":"350_CR30","doi-asserted-by":"publisher","first-page":"15191","DOI":"10.1073\/pnas.261452898","volume":"98","author":"CJ Cohen","year":"2001","unstructured":"Cohen CJ, Shieh JTC, Pickles RJ, Okegawa T, Hsieh J-T, Bergelson JM. The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction. Proc Natl Acad Sci. 2001;98:15191\u20136. https:\/\/doi.org\/10.1073\/pnas.261452898 .","journal-title":"Proc Natl Acad Sci"},{"key":"350_CR31","doi-asserted-by":"publisher","first-page":"e1001122","DOI":"10.1371\/journal.ppat.1001122","volume":"6","author":"BD Persson","year":"2010","unstructured":"Persson BD, Schmitz NB, Santiago C, Zocher G, Larvie M, Scheu U, et al. Structure of the extracellular portion of CD46 provides insights into its interactions with complement proteins and pathogens. PLoS Pathog. 2010;6:e1001122. https:\/\/doi.org\/10.1371\/journal.ppat.1001122 .","journal-title":"PLoS Pathog"},{"key":"350_CR32","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/sj.cgt.7700981","volume":"13","author":"S Ni","year":"2006","unstructured":"Ni S, Gaggar A, Di Paolo N, Li ZY, Liu Y, Strauss R, et al. Evaluation of adenovirus vectors containing serotype 35 fibers for tumor targeting. Cancer Gene Ther. 2006;13:1072\u201381. https:\/\/doi.org\/10.1038\/sj.cgt.7700981 .","journal-title":"Cancer Gene Ther"},{"key":"350_CR33","doi-asserted-by":"publisher","first-page":"e1000189","DOI":"10.1371\/journal.ppat.1000189","volume":"4","author":"S Tuve","year":"2008","unstructured":"Tuve S, Wang H, Jacobs JD, Yumul RC, Smith DF, Lieber A. Role of cellular Heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35. PLoS Pathog. 2008;4:e1000189. https:\/\/doi.org\/10.1371\/journal.ppat.1000189 .","journal-title":"PLoS Pathog"},{"key":"350_CR34","doi-asserted-by":"publisher","first-page":"7968","DOI":"10.1128\/JVI.76.16.7968-7975.2002","volume":"76","author":"N Avvakumov","year":"2002","unstructured":"Avvakumov N, Wheeler R, D\u2019Halluin JC, Mymryk JS. Comparative sequence analysis of the largest E1A proteins of human and simian adenoviruses. J Virol. 2002;76:7968\u201375. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12134001 . Accessed 13 Feb 2018.","journal-title":"J Virol"},{"key":"350_CR35","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature14899","volume":"524","author":"M Saeed","year":"2015","unstructured":"Saeed M, Andreo U, Chung H-Y, Espiritu C, Branch AD, Silva JM, et al. SEC14L2 enables pan-genotype HCV replication in cell culture. Nature. 2015;524:471\u20135. https:\/\/doi.org\/10.1038\/nature14899 .","journal-title":"Nature"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0350-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-018-0350-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0350-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T17:20:21Z","timestamp":1661448021000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0350-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,13]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["350"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0350-x","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,13]]},"assertion":[{"value":"17 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All mice were housed and treated in accordance with UK Home Office guidelines outlined in the Animals (Scientific Procedures) Act 1986.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"KDF, BC and LWS hold equity in PsiOxus Therapeutics Ltd. KW, FL, LS, AB and BC are employees of Psioxus Therapeutics Ltd. JL, EJJ, MRD, and SH declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"55"}}